On the morning of April 8, Deqi Pharmaceutical announced on the Hong Kong Stock Exchange that on April 7, 2025, the board of directors decided to use share repurchase authorization and repurchase shares on the open market from time to time at a maximum total price of HK$40 million according to market conditions. The Company will make a proposed share repurchase in accordance with the Company's Articles of Association, the Hong Kong Stock Exchange Limited Securities Listing Rules, the “Code on Company Acquisitions, Mergers and Share Repurchases”, the Cayman Islands Companies Act, and all applicable laws and regulations that the company must abide by. The board of directors may later cancel the purchased shares or hold treasury shares by the company in accordance with the market conditions at the time of the repurchase and the Group's capital management needs. The company will fund the proposed share repurchase from its internal resources.

On the morning of April 8, Deqi Pharmaceutical announced on the Hong Kong Stock Exchange that on April 7, 2025, the board of directors decided to use share repurchase authorization and repurchase shares on the open market from time to time at a maximum total price of HK$40 million according to market conditions. The Company will make a proposed share repurchase in accordance with the Company's Articles of Association, the Hong Kong Stock Exchange Limited Securities Listing Rules, the “Code on Company Acquisitions, Mergers and Share Repurchases”, the Cayman Islands Companies Act, and all applicable laws and regulations that the company must abide by. The board of directors may later cancel the purchased shares or hold treasury shares by the company in accordance with the market conditions at the time of the repurchase and the Group's capital management needs. The company will fund the proposed share repurchase from its internal resources.